IPF is a rare disease, in which patients are most often affected from middle age, and its manifestation is characterised by severe, irreversible interstitial fibrosis with seriously limited survival of three years from the initial diagnosis. Despite the existing therapies and efforts exerted in research to develop new therapies, IPF is still an incurable, fast progressive condition with poor prognosis. Dr. Zoltán Vincze, Dr. Emília Balogh and Dr. Mohamed El Malt of Europital discuss the symptomatic treatment and management of complications.